Global X Genomics & Biotechnology ETF

Global X Genomics & Biotechnology ETF (GNOM) is an index fund. It tracks the Solactive Genomics Index, a basket of about 50 healthcare companies that work in gene editing, DNA sequencing, genetic medicines and genetic testing. Its 0.50% expense ratio is below the 0.56% average for similar funds and well under the 0.75% charged by ARK Genomic Revolution ETF. It is very volatile: it fell 75% between February 2021 and April 2025.

• Over the year to Oct 27, 2026, GNOM returned +56.6%, 2nd of 9 among similar funds.
• Its 5-year annualized return was -3.9%.
• In the 2020 COVID crash it fell 33.8% and regained its old high 2 months after the low.
• Its worst full calendar year was 2022 (-36.3%); its best was 2020 (+51.5%).
• The deepest fall in its price history was 75% (Feb 8, 2021 to Apr 8, 2025), not yet recovered.

As of May 31, 2026, the fund held 51 securities; the ten largest made up 42.54% of assets.

• Over the three months to May 31, 2026, investors added a net $1.4M (creations minus redemptions, per the N-PORT report).
• Monthly total returns reported for that quarter: +9.61%, +3.45%, -8.57%.

GNOM aims to match the Solactive Genomics Index, before fees. Solactive AG, the index provider, starts with listed companies that FactSet classifies as healthcare. They must trade in the US, Canada, Japan, much of Europe or a few other developed markets. ADRs (US-traded receipts for foreign shares) of emerging-market companies also qualify. As of January 31, 2026, a company needed a market value of at least $200 million and average daily trading of at least $2 million. Software that reads filings and earnings-call transcripts then ranks companies by how directly they work in genomics. Solactive checks that each one is involved in gene editing, genomic sequencing, genetic medicines, or computational genomics and diagnostics.

The index favors 'pure plays.' These are the 20 top-ranked companies that earn at least half their revenue from genomics, plus genomics companies with no revenue yet. Up to five top-ranked diversified firms, with less than half their revenue from genomics, can also join. No more than ten such firms can be in the index at once, at up to 2% each and 10% combined. The index holds at most 50 stocks. It had 49 as of January 31, 2026.

Stocks are weighted by the market value of their freely traded shares. At each twice-yearly rebalance, no company can be more than 4%. Between rebalances, winners can grow past that cap: Guardant Health was 5.6% of the fund as of May 31, 2026. The fund may also lend out up to one-third of its assets.

• GNOM charges 0.5% a year, versus an average of 0.56% for the similar funds below (3rd of 9, cheapest first).
• Using the prospectus's standard example, $10,000 invested would cost about $51 in the first year and $628 over 10 years (assuming a 5% annual return).

GNOM is a narrow bet on one corner of healthcare with large swings, so it fits better as a small side position than as a foundation.

GNOM adds focused exposure to genomics companies, and its history shows how hard that can be to hold. The fund fell 33.8% in the 2020 COVID crash and recovered in about two months. Then it dropped 46.6% between January and June 2022 and lost 36.1% over calendar 2022, its worst year. From its February 2021 peak, it fell 75% by April 2025. As of October 27, 2026, it still had not gotten back to that peak, even after gaining 51.5% in 2026 through that date. It launched in 2019, so it has no 2008 record. Someone who had to sell shares in a bad year could have locked in deep losses. Income is small: the yield was 0.94% as of October 27, 2026, paid twice a year. Under the SEC's standard example, costs come to about $51 in the first year on $10,000. Past results don't predict the future, and a plan should look at the whole portfolio, not one fund.

Matched by holdings overlap from the latest N-PORT reports.